50-state licensed · 10 U.S. patents · UPS Healthcare logistics · Est. 2013
Enter the U.S. market with licensing, logistics, technology, and compliance - handled.
Buy direct from the manufacturer. Transparent pricing. No GPO required.
Supply chain intelligence and country-of-origin verification at national scale.
iRemedy delivers pharmaceuticals, biologics, medical devices, and supplies directly from manufacturers to the facilities that use them - hospitals, compounding pharmacies, independent pharmacies, clinics, and government agencies.
Every order carries transparent pricing, DSCSA serialization, and auditable chain of custody. Where Made in America alternatives exist, we source them - because domestic supply is not just a preference, it's a national security imperative.
MetaCommerceRx is iRemedy's AI-powered procurement platform - normalizing product catalogs across suppliers, automating DEA/FDA license verification, managing DSCSA serialization, and surfacing real-time cost and availability. Protected by 10 granted U.S. patents.
Branded customer portal, order management, ERP and clinical system integrations - live in 2-4 weeks.
Multi-supplier ordering, real-time inventory, transparent pricing - one platform.
Operation Warp Speed · 500M+ units delivered · Senate testimony on supply chain resilience
iRemedy Healthcare Companies is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. Our logistics infrastructure is powered by UPS Healthcare.
iRemedy distributes pharmaceuticals (branded, generic, and specialty), biologics including IVIG, medical devices, med-surg supplies, and controlled substances. All products are distributed with full DSCSA serialization, transparent pricing, and auditable chain of custody.
iRemedy provides direct manufacturer-to-provider distribution without the GPO markup layers, rebate complexity, or pricing opacity that define legacy distribution. Our AI-powered platform (MetaCommerceRx) automates license verification, catalog normalization, and compliance - and our TradeSpy intelligence engine provides country-of-origin verification that traditional distributors don't offer.
TradeSpy is iRemedy's autonomous supply chain intelligence platform. It continuously verifies the true country of origin for pharmaceutical products sold in the United States, mapping actual API manufacturing locations against FDA labeler records. TradeSpy currently monitors over 129,000 NDCs and identifies foreign adversary exposure, supply chain concentration risk, and domestic American-made alternatives.
The Incubator program provides emerging medical product companies with a complete U.S. market entry solution - warehousing, fulfillment, licensing, compliance, technology, and distribution - as a single managed service powered by UPS Healthcare infrastructure. It compresses market entry from 12-18 months to weeks.
iRemedy serves hospitals and health systems, 503A and 503B compounding pharmacies, independent pharmacies, clinical providers, government agencies (federal and state), and medical product manufacturers entering or expanding within U.S. distribution.
Yes. iRemedy holds 10 granted U.S. patents covering AI-driven supply chain automation, catalog normalization, and procurement intelligence, co-invented with Jim Harding - a co-inventor of MS-DOS and Amazon Marketplace technology.
iRemedy's TradeSpy platform autonomously cross-references manufacturer claims against FDA facility data, import records, and inspection histories to identify discrepancies that indicate counterfeit products, misrepresented country of origin, phantom manufacturers, and quality documentation fraud. iRemedy's direct distribution model also eliminates the opaque intermediary layers where pricing fraud and product substitution typically occur.
MetaCommerceRx - AI-powered procurement, compliance automation, and supply chain intelligence. 100% proprietary. Patent-protected. Running in production.
MetaCommerceRx replaces the fragmented, paper-driven procurement systems that still define healthcare distribution. It connects manufacturers, distributors, providers, pharmacies, and government buyers into a single federated network - with compliance logic, credential verification, and supply chain intelligence built directly into the transaction layer.
This is not a generic e-commerce system adapted for healthcare. It is purpose-built for regulated environments where every order must verify DEA authorization, validate state pharmacy licenses, enforce DSCSA serialization, manage controlled substance protocols, and route fulfillment through compliant cold chain logistics - automatically, on every transaction.
Intelligent catalog normalization across suppliers, automated pricing comparison, and predictive availability - powered by patented Meta.Agent technology that retrieves real-time data from manufacturers, wholesalers, and regulatory sources.
Built-in workflows for DEA/FDA license verification, DSCSA serialization, chain of custody documentation, controlled substance handling, and state board of pharmacy credential validation. Compliance is the default, not an add-on.
Real-time stock levels, lot numbers, expiration dates, temperature excursion alerts, and serialization data across UPS Healthcare facilities and manufacturer locations - one source of truth for every participant.
Every order is automatically routed to the optimal fulfillment path based on warehouse location, product availability, regulatory requirements, cold chain needs, and customer credentials - without human intervention.
MetaCommerceRx is built as a four-layer architecture that separates customer-facing portals, data processing, AI intelligence, and logistics execution into independently scalable components - while keeping them tightly integrated through a unified API layer.
Python / FastAPI backend · React / TypeScript frontend · 100% proprietary - no white-label platform or third-party e-commerce base
MetaCommerceRx isn't protected by contracts or market position - it's protected by a patent portfolio covering the fundamental architecture of AI-driven healthcare procurement. The patents were co-invented with Jim Harding, whose prior work includes co-inventing MS-DOS and the Amazon Marketplace technology.
The portfolio covers automated procurement pathways, multi-role organizational ordering hierarchies, marketplace-style catalog management for healthcare products, intelligent order routing based on licensure and compliance rules, and transaction telemetry for shortage forecasting. Together, they create a technical moat that competitors cannot replicate without infringing.
Patent-protected methods for automating the end-to-end procurement process in regulated healthcare environments - from product discovery through order fulfillment.
The Meta.Agent system that autonomously retrieves, normalizes, and cross-references product data from third-party sources including distributors, manufacturers, and regulatory databases.
Architecture supporting complex purchasing structures - multiple roles, approval workflows, budget authorities, and credential-gated access within and across organizations.
Decision engines that automatically determine fulfillment path, warehouse selection, regulatory check requirements, cold chain necessity, and customer credential matching.
AI-powered normalization of fragmented product catalogs across hundreds of manufacturers and suppliers into a unified, searchable, comparable product intelligence layer.
Telemetry systems that use order flow data to predict demand patterns, identify potential shortages, and generate actionable supply chain intelligence.
Jim Harding co-invented MS-DOS and the Amazon Marketplace technology. His co-inventorship on the MetaCommerceRx patent portfolio places iRemedy's IP in the same lineage as two of the most commercially significant software inventions of the last 40 years.
Every Incubator and DaaS manufacturer gets MetaCommerceRx configured for their products, their customers, and their brand. It's not a shared portal or a generic storefront - it's a dedicated procurement system running on patented infrastructure.
White-labeled ordering experience. Your brand, your product catalog, your pricing - iRemedy's infrastructure behind it. Customers see your company, not ours.
Automated order capture from multiple channels - marketplaces, ERPs, webstores, call centers, API/EDI. Reduces manual handling and ensures DSCSA-compliant processing.
Connects to your ERP, CRM, accounting, and clinical systems. MVP go-live in 2-4 weeks; additional integrations within 30 days.
For hospitals, pharmacies, clinics, and government buyers, MetaCommerceRx provides a single procurement interface across every supplier in the iRemedy network. Compare pricing, verify availability, place orders, and track fulfillment - without logging into a dozen different vendor portals.
Multi-supplier product catalog with live pricing and availability. Compare across manufacturers in real time - no phone calls, no RFQs, no waiting.
DEA, NPI, and state license validation on every transaction. The system won't process an order to an unverified entity - protecting both buyer and seller.
Configurable dashboards for spend analysis, product velocity, compliance status, and DSCSA audit trails. Exportable reports for internal and regulatory use.
TradeSpy is integrated directly into MetaCommerceRx - providing country-of-origin verification, foreign adversary exposure flags, and domestic alternative sourcing at the point of procurement. Buyers don't need a separate intelligence tool. The intelligence is embedded in every product listing, every order decision, and every compliance report.
We'll walk you through MetaCommerceRx configured for your use case - manufacturer, buyer, or government. Live demo, not a slide deck.
Buy pharmaceuticals direct from the manufacturer. Same product, transparent price, auditable chain of custody.
iRemedy Direct delivers pharmaceuticals, biologics, and medical supplies directly to providers, pharmacies, and government buyers - without the GPO markup, rebate complexity, or opacity that defines legacy distribution.
Traditional distributors add 3-7 layers between manufacturer and patient. Each layer adds cost, removes visibility, and creates a point of failure. iRemedy Direct compresses that to one.
Manufacturers without full U.S. distribution licensure use iRemedy as the regulatory pass-through. We hold the license. You own the customer relationship.
MetaCommerceRx runs the orders. TradeSpy runs the intelligence. Both are live, both are production.
Built on patented AI automation, MetaCommerceRx handles SKU normalization, DEA/FDA license verification, DSCSA serialization, real-time inventory, and multi-tier ordering - as a managed service.
Standard integration: $5,000/month (12-month term) · MVP go-live: 2-4 weeks
Real-time exposure mapping for every NDC in your formulary. Country of origin. Manufacturer risk. Shortage probability. Domestic alternatives.
Every adversary-exposed product in America's supply chain hides in one of three layers. Most current procurement and policy systems see only the third.
State-owned enterprises, MIC2025-designated firms, BIOSECURE-listed entities, NPC-affiliated executives, party-committee structures inside ostensibly commercial manufacturers. The political architecture behind the supplier - invisible to sanctions screening, invisible to procurement databases.
Active pharmaceutical ingredient manufacturing locations, import records, Drug Master File filings, customs declarations. Where things are physically made - which routinely differs from where they are labeled, sold, or shipped from.
"Manufactured For" shell arrangements, U.S. headquarters conflation, contract-manufacturing cascades, repackager attribution. The layer current systems can see - and the layer adversaries optimize against.
TheTradeSpy verifies all three. Every determination carries its source, its timestamp, and its confidence tier. The audit trail is the product.
The reason supply chain surveillance has historically failed is not a lack of will. It is a lack of scale. There are too many products, too many manufacturers, too many shell layers, and too many data sources for any human team to monitor continuously. TheTradeSpy removes that ceiling.
Large language models identify the products that matter, define the evidence required to verify them, and design the specifications for the field agents that will collect that evidence.
Agent specifications are reviewed, hardened, and deployed by iRemedy engineers. No agent is created, modified, or released into production without human authorization.
Field Agents collect evidence from federal and commercial sources. Scoring Agents apply a deterministic 63-factor model. An independent Reconciler validates every conclusion. A Data Inspector flags discrepancies, stale data, and scoring drift.
More than 80 percent of generic active pharmaceutical ingredients are sourced from India and China. A single supply disruption can produce a national shortage within weeks. The agencies responsible for protecting service members, veterans, and the broader population had no continuous visibility into where their drugs were actually made.
That gap is now closed - in both directions. TheTradeSpy continuously surveils the pharmaceutical supply chain for adversary exposure, and continuously verifies which products are made in America with sufficient evidentiary confidence to support federal procurement decisions.
Every data point carries its source, its collection timestamp, and its confidence contribution. Every score is reproducible to the field level. Same inputs produce identical outputs - every time.
Core risk and origin scoring runs in Python and SQL - rule-based, transparent, and reviewable. Language models design strategy and articulate findings. They do not assign risk.
A manufacturer flagged through any of fifteen institutional risk sources cannot have that flag overridden by a quality certification, a domestic-bonus adjustment, a self-attestation, or a human reviewer. Enforced in code.
No agent is created, modified, or released into production without engineering review and explicit human authorization. The platform automates surveillance. It does not automate the decision to surveil.
TheTradeSpy aligns with the requirements and recommendations set out in OMB Memorandum M-25-22, Driving Efficient Acquisition of Artificial Intelligence in Government.
For national security and defense readers - for whom M-25-22 is explicitly out of scope - the same architectural commitments map directly to governing AI in NSS environments.
Supply chain fraud in pharmaceuticals is not a hypothetical - it is a documented, recurring failure in the U.S. drug supply. Counterfeit products enter through unverifiable chains. Manufacturers misrepresent where drugs are made. Quality records are falsified at facilities that haven't seen an FDA inspector in years. Pricing is inflated through layers of middlemen who exist to extract margin, not add value.
TradeSpy treats every data discrepancy as a potential fraud signal. When an FDA labeler address doesn't match the actual manufacturing facility - that's a signal. When a product claims domestic origin but the API traces to an uninspected foreign plant - that's a signal. When a facility has a pattern of FDA warning letters but product continues to flow into the U.S. market - that's a signal.
Traditional compliance systems flag these issues after the fact, if at all. TradeSpy surfaces them before the product enters the formulary - turning reactive fraud investigation into proactive fraud prevention.
TheTradeSpy is built by iRemedy Healthcare. Over the past fifteen years, iRemedy has imported more than 1.1 billion units of medical product for the Department of Defense, the Department of Veterans Affairs, federal agencies, and U.S. healthcare systems.
The team holds direct operational experience from Operation Warp Speed and has testified before the United States Senate on supply chain vulnerability and the imperative for reshoring critical manufacturing.
iRemedy is committed to working closely with private and public stakeholders advancing Made in America procurement priorities.
TheTradeSpy is available on a controlled-access basis. Briefings, pilot integrations, and licensing discussions are conducted directly with iRemedy leadership.
UPS Healthcare infrastructure, iRemedy compliance, white-label fulfillment. Cold chain, DEA, DSCSA - handled.
1-2 day reach to 95% of the U.S. population. cGMP/GDP-compliant facilities, cold chain infrastructure, and controlled substance vault capability across the network.
iRemedy provides white-label fulfillment for manufacturers and distributors who need logistics capability without building it in-house. Your brand on the box, our compliance behind it.
For emerging medical product companies, iRemedy provides licensing, technology, logistics, and distribution as a managed service. Bring the product. We handle the rest.
The Incubator compresses U.S. market entry from 12-18 months to weeks. We provide everything a manufacturer needs to sell compliantly into the U.S. healthcare market - warehousing, fulfillment, licensing, technology, and distribution - as a single managed service.
Pricing: $5K-$15K/month · Onboarding: weeks, not months
The Incubator is purpose-built for manufacturers entering U.S. healthcare distribution - domestic startups, international companies seeking U.S. market access, and established players launching new product lines.
The Incubator is not a consulting engagement. It's infrastructure - operational from week one, built to scale with your volume.
Licensing, logistics, compliance, technology, and distribution - as a managed service powered by UPS Healthcare.
50-State Licensed · DSCSA Compliant · 10 U.S. Patents · UPS Healthcare 3PL
Medical product companies - domestic startups, international manufacturers, and established players launching new lines - face the same structural problem: U.S. healthcare distribution requires an interlocking stack of federal and state licenses, DEA authorization, DSCSA serialization infrastructure, compliant warehousing, cold chain capability, and technology integration. Building that stack from scratch costs millions and takes 12-18 months.
Traditional distributors won't help. They either refuse sub-enterprise volume, impose prohibitive minimums, or offload compliance responsibility back onto the manufacturer. The result: promising products never reach the providers who need them.
For international manufacturers, the challenge is compounded. Entering the U.S. healthcare market from outside the country means navigating FDA registration, DEA authorization, state-by-state licensing, customs and import compliance, and a distribution infrastructure that U.S. buyers expect to be fully operational before they'll place a first order. iRemedy eliminates that entire buildout.
iRemedy closes that gap.
Whether you need a full-stack market entry solution or a regulatory pass-through for an established product, iRemedy provides the distribution infrastructure. You choose the model that fits.
For manufacturers entering U.S. healthcare distribution - or scaling without building internal operations. iRemedy provides warehousing, fulfillment, licensing, compliance, technology, and distribution as a single managed service.
You bring the product. We handle everything else.
For manufacturers with existing customer relationships who need a licensed distribution pass-through. iRemedy acts as seller-of-record, providing the regulatory envelope while you maintain the customer relationship.
Every Incubator client gets MetaCommerceRx - iRemedy's AI-powered procurement platform - configured for their products, their customers, and their brand. It's not a shared portal. It's your own ordering system, running on patented infrastructure.
The Incubator program is designed for companies entering or scaling within U.S. healthcare distribution. If you have a product that's ready for market and need the infrastructure to sell it compliantly nationwide, this is the fastest path.
The Incubator is selective. We don't onboard commodity-only accounts, companies unwilling to adopt required technology, or products that cannot meet compliance standards.
iRemedy has served as the U.S. distribution partner for international manufacturers across pharmaceuticals, medical devices, and medical supplies - providing the complete regulatory, logistics, and technology stack required to sell compliantly into U.S. healthcare.
We handle what most international companies spend years trying to build on their own:
Whether you're a pharmaceutical manufacturer in Shanghai, a device company in Mumbai, or a med-surg supplier in Frankfurt - the infrastructure is the same, the compliance is the same, and the speed to market is the same.
The Incubator program is priced at $5,000-$15,000 per month depending on product complexity, storage requirements, and volume. Additional fees may apply for special handling, custom packaging, or international freight. We provide a detailed proposal before any commitment.
Typical onboarding is 2-6 weeks from signed agreement to first shipment. MetaCommerceRx platform integration is typically live within 2-4 weeks.
The Incubator is the full-stack solution - warehousing, fulfillment, licensing, compliance, technology, and distribution all managed by iRemedy. DaaS (Distributor-as-a-Service) is a lighter-touch model where iRemedy acts as the licensed seller-of-record while you maintain direct customer relationships. DaaS is best for manufacturers who already have customers but need regulatory coverage.
Pharmaceuticals (branded, generic, specialty), biologics including IVIG, medical devices, med-surg supplies, and controlled substances (DEA Schedule II-V). We handle ambient, refrigerated, frozen, and ultra-cold storage environments.
No. In the Incubator model, iRemedy holds all required federal and state licenses. In the DaaS model, iRemedy acts as seller-of-record under our license stack. Either way, you don't need to build your own.
Yes. In the DaaS model, you maintain all customer relationships and pricing. In the Incubator model, customers can order through your branded portal powered by MetaCommerceRx.
Agreements renew by mutual consent. Many Incubator clients grow into direct UPS Healthcare accounts over time - the Incubator is designed as a bridge to enterprise-scale operations, not a permanent dependency.
Traditional healthcare distribution runs through layers - manufacturers, wholesalers, GPOs, distributors, sub-distributors - each adding cost, removing visibility, and creating incentive structures that don't align with the buyer's interest. GPOs negotiate "discounts" funded by supplier fees that inflate the base price. Distributors add markups that aren't visible on the invoice. Rebates flow backward, not forward. The result: hospitals routinely overpay for commodity products and have no mechanism to verify whether the price they're paying is competitive.
iRemedy removes the layers. You buy direct from the manufacturer through a single licensed distributor with transparent pricing, auditable chain of custody, and compliance built into every transaction.
No rebate games. No hidden markups. No three-year lock-in contracts.
iRemedy Direct serves any licensed healthcare facility that purchases pharmaceuticals, biologics, medical devices, or supplies. Whether you're a multi-site health system looking for a transparent alternative to your current distributor or an independent clinic that's been priced out of competitive purchasing, the infrastructure is the same.
Most hospitals are contractually tied to GPO arrangements - and iRemedy isn't asking you to break those contracts. But every health system has non-contract categories, backfill needs during shortages, and product lines where the GPO price isn't actually competitive. iRemedy operates as a parallel channel that gives you leverage, optionality, and pricing transparency on the categories where your current arrangement isn't serving you.
Some providers start with a single product category - specialty pharmaceuticals, compounding ingredients, or a specific device line. Once they see the pricing transparency and operational simplicity, the relationship grows.
Over time, the question shifts from "should we use iRemedy?" to "why are we paying more through our GPO for the same product?"
Every order ships through UPS Healthcare's distribution network - the same infrastructure used by the world's largest pharmaceutical companies. 1-2 day delivery to 95% of the U.S. population. Cold chain monitoring from warehouse to your dock. DSCSA serialization on every shipment.
iRemedy has delivered more than 500 million units under federal contract, including Operation Warp Speed. Our CEO has testified before the U.S. Senate on supply chain resilience. Our technology is protected by 10 granted U.S. patents. This isn't a startup pitch - it's infrastructure that's been operating for nearly two decades.
iRemedy provides transparent, manufacturer-direct pricing without rebate layers or hidden distribution markups. For many product categories - particularly specialty pharmaceuticals, compounding ingredients, and non-contract items - iRemedy pricing is meaningfully lower than GPO-contracted pricing because there are fewer intermediaries adding cost. We encourage buyers to compare directly.
Yes. Most providers use iRemedy as a secondary or parallel channel - for non-contract items, backfill during shortages, or categories where iRemedy pricing is more competitive. There's no membership fee and no exclusivity requirement.
Pharmaceuticals (branded, generic, specialty), biologics including IVIG, medical devices, med-surg supplies, and DEA Schedule II-V controlled substances. The catalog includes over 1 million products through MetaCommerceRx.
Orders are placed through MetaCommerceRx - iRemedy's online procurement platform. You can also integrate with your existing ERP or ordering system via API. Orders are fulfilled through UPS Healthcare and delivered in 1-2 business days to most U.S. locations.
Yes. Every transaction includes full DSCSA serialization - transaction history, transaction statement, and transaction information. Compliance is built into the platform, not added as a manual step.
iRemedy does not impose the volume minimums that traditional distributors require. Whether you're a multi-site health system or an independent clinic, the platform and pricing are accessible.
Through TradeSpy integration, every product in the iRemedy catalog includes verified country-of-origin data for both the finished dosage form and the active pharmaceutical ingredient. This is particularly relevant for facilities with Buy American requirements or internal sourcing policies.
Compounding pharmacies face an impossible combination: unprecedented demand for peptide and GLP-1 therapies, tightening FDA enforcement, and a wholesale market flooded with APIs of unverifiable origin. Import holds, cGMP violations, and untraceable chains of custody have disrupted pharmacies across the country - and the cost of sourcing from the wrong supplier isn't a fine, it's your license.
Independent retail pharmacies face a different version of the same problem: locked into distributor contracts with opaque pricing, volume minimums that don't fit their scale, and no visibility into where products actually come from.
iRemedy solves both problems with the same infrastructure: a fully credentialed distribution platform where every product - from bulk API to finished pharmaceutical - carries documented origin, auditable chain of custody, and pharma-grade logistics from warehouse to your receiving dock.
Peptide APIs require validated cold chain logistics - not a styrofoam box with a gel pack. iRemedy's fulfillment runs through UPS Healthcare, providing temperature-controlled storage and transport from warehouse to pharmacy. Ambient, refrigerated, frozen, and ultra-cold environments - monitored continuously, documented automatically.
This is the same logistics network used by the world's largest pharmaceutical manufacturers, deployed for compounding pharmacies that have historically been too small to access it.
MetaCommerceRx gives pharmacy buyers a single procurement interface for APIs, finished pharmaceuticals, and supplies across multiple suppliers. Real-time inventory visibility, automated credential verification, DSCSA compliance on every transaction, and order tracking from warehouse to your dock.
iRemedy is building the definitive peptide distribution infrastructure for U.S. compounding pharmacies - combining FDA-credentialed API sourcing, validated cold chain logistics, and the compliance documentation that separates legitimate supply from regulatory risk.
GLP-1 agonists, BHRT hormones, wellness peptides, men's health, and specialty compounds - sourced from verified manufacturers, imported under iRemedy's credentials, stored and shipped through UPS Healthcare's pharma-grade network.
iRemedy operates outside the traditional wholesale model that penalizes small and mid-size pharmacies with opaque markup structures and multi-year commitments. Every product shows a visible price. APIs are quoted with full documentation of source, lot, and import credentials included - not as an add-on.
Whether you're ordering a single gram of Tirzepatide API or building a recurring supply relationship across 50 compounding ingredients, the pricing model is the same: transparent, competitive, and documented.
Yes. iRemedy supplies Tirzepatide, Semaglutide, and other GLP-1 agonist APIs for compounding under 503A and 503B. All GLP-1 APIs are sourced from FDA-registered, Green List manufacturers, and iRemedy serves as the U.S. Importer of Record. Full certificate of analysis, lot documentation, and import records are provided with every order.
For every API - especially GLP-1s and peptides - iRemedy verifies the manufacturer's FDA registration (FEI number), Green List status under relevant Import Alerts, cGMP inspection history, and lot-specific certificate of analysis. iRemedy is named as U.S. Importer of Record on customs documentation, meaning the regulatory chain of custody runs through us, not through an offshore broker.
All peptide and temperature-sensitive APIs are stored and shipped through UPS Healthcare's pharma-grade cold chain network. This includes ambient, refrigerated (2-8°C), frozen (-20°C), and ultra-cold environments with continuous monitoring and documentation. This is validated pharmaceutical logistics - not consumer-grade courier.
Yes. iRemedy does not impose the volume minimums that traditional wholesalers require. The platform and pricing are accessible to single-location independents and multi-site operations alike.
iRemedy is a licensed wholesale distributor - NABP accredited, licensed in all 50 states, and DSCSA compliant. We are not a broker. Products are warehoused, handled, and shipped through our own licensed infrastructure powered by UPS Healthcare.
Yes. iRemedy distributes Schedule II through V controlled substances. All controlled substance orders include full DSCSA serialization and chain-of-custody documentation.
iRemedy is developing a dedicated peptide distribution hub and education platform at peptides.iremedy.com - featuring detailed API product information, regulatory guidance, clinical protocol resources, and direct ordering for compounding pharmacies. Contact our compounding team for early access.
Educational purposes only. The information presented in this Peptide Intelligence Hub is compiled from published, peer-reviewed scientific literature and is provided for educational and informational purposes only. It does not constitute medical advice, clinical guidance, or a recommendation to use any specific compound. Evidence grades are assigned by iRemedy based on the quality and quantity of available clinical literature as of the publication date and are subject to revision as new research emerges. Peptide sourcing and distribution is subject to applicable DEA, FDA, and state pharmacy board requirements. Compounding use requires a valid physician prescription under applicable 503A/503B regulations. iRemedy does not sell peptides directly to patients or consumers. All sourcing is wholesale-only to licensed healthcare facilities and compounding pharmacies.
We detect supply chain fraud, identify foreign adversary exposure, and verify country of origin across the U.S. pharmaceutical supply. Then we provide the American-made alternative - and the distribution economics to make it viable.
Decades of offshoring have left American healthcare dangerously exposed. The distribution system that delivers medicine to U.S. hospitals, pharmacies, and military facilities was built for a globalized world - optimized for cost, not resilience. The result is a supply chain where adversarial nations control the upstream manufacturing of products Americans depend on to stay alive.
COVID exposed stock-outs of PPE, syringes, and critical medicines nationwide.
Over 80% of FDA drug-quality warning letters (2013-2023) went to foreign facilities.
Adversarial nations can cut off medicine flow without firing a shot.
Drug shortages alone cost U.S. healthcare $400M+ annually in workarounds.
Healthcare supply chain fraud is not an edge case - it is systemic.
Counterfeit pharmaceuticals enter the U.S. market through unverifiable intermediary chains.
Manufacturers misrepresent country of origin to circumvent tariffs, Buy American requirements, and FDA oversight.
Pricing is inflated through layers of opaque middlemen who add cost without adding value.
Quality documentation is falsified at facilities that receive an FDA inspection less than once per decade.
The federal government spends billions on healthcare procurement.
A meaningful percentage of that spend flows through supply chains where fraud is not just possible - it is structurally incentivized by opacity, distance, and the absence of verification infrastructure.
iRemedy's AI-powered platform attacks fraud at every layer:
TradeSpy cross-references manufacturer claims, FDA registration data, lot documentation, and import records to identify products where the stated origin doesn't match the documented manufacturing chain. When the paperwork doesn't trace back to a real, inspected facility - that's a fraud signal.
Manufacturers and intermediaries misrepresent where products are made - claiming domestic or allied-nation origin for products actually manufactured in adversarial or non-compliant jurisdictions. TradeSpy verifies actual API manufacturing location against FDA facility data, import records, and customs documentation.
Some FDA labeler records point to entities that don't manufacture anything - they're administrative shells that obscure the true production source. TradeSpy maps the actual manufacturing chain behind every NDC, identifying where the real production happens vs. where the paperwork says it does.
Legacy multi-tier distribution adds 15-30%+ in intermediary markups that are invisible to the buyer. Each layer creates an opportunity to inflate pricing without accountability. iRemedy Direct distribution eliminates those layers - making pricing transparent and auditable from manufacturer to point of care.
Foreign facilities with infrequent, pre-announced inspections have well-documented patterns of falsifying quality records, substituting materials, and manipulating test results. TradeSpy flags products sourced from facilities with FDA warning letters, import alerts, or inspection deficiencies - surfacing quality risk before it reaches patients.
MetaCommerceRx automates verification of state pharmacy licenses, FDA establishment registration, and NABP accreditation on every transaction - preventing unlicensed entities from purchasing or distributing controlled substances and regulated products.
Every dollar lost to supply chain fraud is a dollar diverted from patient care. AI-powered verification doesn't eliminate fraud by catching it after the fact - it eliminates the conditions that make fraud possible in the first place.
TradeSpy is iRemedy's autonomous supply chain intelligence platform. It continuously verifies the true country of origin for pharmaceutical products sold in the United States - mapping actual API manufacturing locations, flagging CCP-controlled supply chain exposure, identifying geopolitical transit risk, and surfacing domestic American-made alternatives.
Federal procurement teams currently have no systematic way to verify whether the drugs in their formulary are manufactured by CCP-controlled entities, transit the Strait of Hormuz, or have viable domestic alternatives. TradeSpy closes that gap.
TradeSpy is also a fraud detection engine. By autonomously cross-referencing manufacturer claims against FDA facility data, import records, inspection histories, and real-world production intelligence, TradeSpy identifies the discrepancies that indicate counterfeit product, misrepresented origin, phantom manufacturers, and quality documentation fraud - before those products enter the formulary.
Maps the actual manufacturing location of active pharmaceutical ingredients - not just the FDA labeler address. Traces through contract manufacturers, intermediaries, and API suppliers to identify true origin.
Identifies pharmaceutical products with manufacturing ties to Chinese Communist Party-controlled entities, CCP-affiliated state-owned enterprises, and facilities subject to U.S. sanctions or export controls.
Flags supply chains transiting the Strait of Hormuz, South China Sea, and other geopolitical chokepoints. Models disruption scenarios and quantifies formulary-level exposure.
For every flagged product, TradeSpy identifies American-made and allied-nation alternatives - enabling formulary-level reshoring decisions backed by data rather than aspiration.
Aligns with federal Made in America requirements and OMB Memorandum M-25-22 guidance on supply chain risk assessment and domestic sourcing verification.
Monitors congressional activity, FDA enforcement actions, and policy developments affecting pharmaceutical supply chain requirements - connecting policy changes to specific products in your formulary.
The conventional argument is that American-made medical products can't compete on price with foreign alternatives. That's wrong - but not for the reason most people think.
Much of what looks like a foreign price advantage is actually a distribution-layer problem. The legacy multi-tier distribution model - importers, national wholesalers, regional distributors, GPO rebates and fees - was an outgrowth of globalization, built to connect distant foreign factories to U.S. buyers through layers of intermediaries. Each layer adds 15-30%+ in cost.
Domestic production doesn't need that infrastructure. When you remove the import chain, the wholesaler margin, the distributor markup, and the GPO fee structure, much of the foreign "price advantage" disappears - and American manufacturers become price-competitive without federal subsidies doing all the work.
There is a second benefit to compressing the supply chain that is rarely discussed: fraud prevention. Every intermediary in a multi-tier distribution chain is an opportunity to introduce counterfeit product, misrepresent origin, inflate pricing, or falsify documentation. Domestic production through direct distribution doesn't just lower cost - it removes the structural conditions that enable supply chain fraud. Fewer layers, shorter chains, continuous FDA oversight, and transparent pricing eliminate the opacity that fraud requires to operate.
Domestic production doesn't need the import and multi-tier infrastructure at all. When you remove those layers, much of the foreign "price advantage" disappears - and U.S. manufacturers become price-competitive without federal subsidies doing all the work.
iRemedy is building the Made in America Portfolio - a curated, certified collection of American-made medical products available through a single distribution and procurement relationship. Every product in the Portfolio has verified domestic manufacturing status. Every order ships through UPS Healthcare's compliant logistics network. Every transaction carries full DSCSA serialization.
For hospitals, health systems, VA facilities, and federal buyers who want to shift procurement toward American-made products - the Portfolio eliminates the operational pain of doing it one vendor at a time.
Hospitals and federal agencies want to buy American. But doing it one SKU at a time is operationally painful:
A single procurement destination where every product is genuinely American-made:
iRemedy has executed at federal scale. During Operation Warp Speed, we delivered over 500 million needles and syringes to the U.S. government - one in every two doses of the COVID-19 vaccine was administered using iRemedy-supplied needles. That experience exposed every vulnerability in the U.S. medical supply chain. It also proved that iRemedy can operate at the speed and scale the federal government requires.
500M+ units delivered under federal contract. Multi-continent surge logistics coordination across international air freight, customs, and last-mile delivery to vaccination sites nationwide.
CEO Tony Paquin testified before the U.S. Senate in the hearing "Bad Medicine: Closing Loopholes That Kill American Patients" - presenting evidence on supply chain vulnerabilities, foreign dependency, and reshoring strategy.
Active participant in the White House Office of Management and Budget working group on federal supply chain resiliency policy, contributing operational intelligence to national procurement reform.
U.S.-based generic drug manufacturer. 120-180M solid oral dosage units/month. iRemedy provides government market advisory for VA, DLA, DoD, and federal procurement channels.
First U.S.-based sterile surgical glove manufacturer. Positioned for government procurement. On the iRemedy platform for commercial launch and go-to-market.
Florida-based IV and saline bag manufacturer. Domestic production of critical infusion products. Entering federal and commercial distribution through the iRemedy Incubator.
50-state licensed, DSCSA-compliant distribution of pharmaceuticals, biologics, devices, and supplies. Ambient to ultra-cold chain.
TradeSpy-powered formulary analysis: CCP exposure, concentration risk, geopolitical transit vulnerability, and domestic alternative identification.
Country-of-origin verification at the product level - supports Buy American Act, BAA/TAA, and Berry Amendment compliance.
Operation Warp Speed-proven capability to scale from routine operations to emergency national distribution.
Real-time visibility into product availability, shelf life, and manufacturer capacity. Shortage early warning through supply chain monitoring.
Incubator program that gives American manufacturers a complete path to federal and commercial distribution - live in weeks, not years.
Whether you need supply chain intelligence, domestic sourcing alternatives, or federal-scale distribution - we'll put together a capability brief tailored to your mission.
Direct contact: Tony Paquin, CEO - tony@iremedy.com
Founded in 2013. Operational through the worst supply chain crisis in modern history. Building the infrastructure the industry still doesn't have.
iRemedy is a technology-enabled healthcare distributor operating at the intersection of AI-powered procurement, compliant logistics, and supply chain intelligence. We distribute pharmaceuticals, biologics, medical devices, and supplies directly from manufacturers to the facilities that use them - hospitals, pharmacies, clinics, and government agencies - across all 50 states.
Our platform, MetaCommerceRx, is protected by 10 granted U.S. patents. Our logistics infrastructure is powered by UPS Healthcare. Our supply chain intelligence platform, TradeSpy, provides autonomous country-of-origin verification and foreign adversary exposure mapping across the U.S. pharmaceutical supply.
We exist because the legacy healthcare distribution system - built on opacity, intermediary markups, and foreign dependency - is a structural vulnerability that cannot be reformed from within. It requires a replacement. That replacement is being built here.
Serial entrepreneur and technology pioneer with 30+ years leading innovations in healthcare procurement, supply chain resilience, and digital systems.
Tony built iRemedy from a healthcare e-commerce startup into a patent-protected, federally credentialed distribution platform. During Operation Warp Speed, he led iRemedy's delivery of over 500 million needles and syringes to the U.S. government - one in every two COVID-19 vaccine doses was administered using iRemedy-supplied needles.
He has testified before the U.S. Senate on pharmaceutical supply chain vulnerabilities, participates in the White House OMB working group on supply chain resiliency, and is a member of the SAMS Coalition. He is the author of "The Retail Healthcare Revolution" (2007) and "The End of Us" (2023).
Prior to iRemedy, Tony founded Agency One (acquired by CNA Financial; became Vertafore, valued at multi-billions), co-founded Netivation (NASDAQ IPO, 1999), and founded the Idaho Technology Association and the Arizona Software & Industry Association.
Anthony Paquin serves as Chief AI Officer of The iRemedy Healthcare Companies, Inc., where he leads the design, development, and deployment of the AI solutions that power iRemedy's mission. He is the architect of iRemedy.ai — a multi-agent supply chain intelligence platform that ingests data from more than 25 federal, regulatory, and international sources to deliver real-time risk scoring, country-of-origin determination, CCP exposure screening, and API dependency analysis across the U.S. pharmaceutical supply chain. The platform is built on a foundation of patented AI technology originally developed by iRemedy for healthcare procurement automation.
Anthony joined iRemedy in December 2013 as Director of Marketing and rose through the ranks to Sales Director in October 2015 and Vice President of Sales and Global Supply Chain in January 2019, where he led worldwide business development, the Incubator partnership with UPS Healthcare, and the Company's MetaCommerce technology platform. In his expanded role as Chief AI Officer, he directs iRemedy's three-pillar strategy — technology, logistics and direct distribution — with a stated vision of operationalizing “hundreds of new capabilities and thousands of AI agents” in concert across the company's supply chain infrastructure.
Anthony's work spans some of the most consequential challenges in U.S. healthcare today: reshoring of medical manufacturing, mitigation of Chinese API dependency, federal procurement modernization, and the operational rollout of direct manufacturer-to-patient/provider models. He is a frequent contributor to iRemedy's federal engagements, including the Company's work with the White House OMB working group on supply chain resiliency, and serves as a primary technology liaison across iRemedy's manufacturer, 3PL, and government partnerships.
Anthony is a graduate of the University of Central Florida, where he earned dual Bachelor's degrees in Business and Behavioral/Social Science, and holds an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. He is based at iRemedy's headquarters in Stuart, Florida.
Amanda Somsy serves as Chief Financial Officer of iRemedy Healthcare Companies, Inc. and as Chief Financial Officer and Board Member of its wholly owned subsidiary, iRemedy Direct, Inc., where she leads finance, treasury, capital strategy, and SEC reporting in support of the Company's planned Nasdaq listing.
Ms. Somsy brings more than 13 years of progressive finance and accounting leadership at iRemedy, having advanced from Controller (2013–2018) to Vice President of Finance (2018–2023) to Chief Financial Officer (2023–present). She has successfully delivered nine consecutive fiscal-year audits (2016–2024) and supported the Company's Regulation A+ capital raise alongside ongoing bridge financing and IP-backed lending initiatives.
Ms. Somsy also served as Consulting CFO to Celebration Health & Wellness (2024–2025), advising on financial operations across affiliated medical practices. She holds a Master of Science in Accounting from Southern New Hampshire University, a Bachelor of Business Administration from Keene State College, and is a Certified Management Accountant (CMA®).
Chair of Nexalin (Nasdaq); former senior executive at Revlon and Disney.
CEO of InfusionCapital; pediatric practice owner; healthcare operations and capital formation expert.
Vice Chair at Cordiant Capital; former BlackRock Managing Director.
Co-founder of iRemedy and Agency One; Stanford and Harvard board-certified sales and leadership expert.
Former Chair of the White House Council of Economic Advisers; leading health economist and policy strategist.
Former President of Global Sourcing and President of Generics at McKesson Corporation.
See how we bring products to market.
Manufacturer Services →See transparent pricing and direct distribution.
Provider Services →See supply chain intelligence and domestic sourcing.
Government Solutions →Whether you're a manufacturer exploring U.S. distribution, a buyer looking for transparent pricing, or a government team evaluating supply chain intelligence - tell us what you need.
iRemedy Healthcare Companies, Inc.
1239 SE Indian Street, Unit 112
Stuart, FL 34994
Press releases, The Supply Side podcast, published articles, and media coverage from iRemedy Healthcare.
Spectrum Medical, a global provider of advanced systems for patient monitoring and perfusion management, joins iRemedy's Healthcare Supply Incubator Program to expand U.S. reach.
Feb 24, 2026 → Read More ↗CEO Tony Paquin's testimony before the U.S. Senate on pharmaceutical supply chain vulnerabilities, foreign dependency, and reshoring strategy.
Oct 13, 2025 → View Testimony ↗Healthcare supply chain policy, national security, reshoring, and the future of American pharmaceutical infrastructure. New episodes weekly.
Listen on YouTube ↗Healthcare supply chain policy, national security, reshoring, and the future of American pharmaceutical infrastructure. New episodes weekly.
A Story of Death, Deception and China's Deadly Grip on US Healthcare. Documents the risks of America's dependency on foreign medical manufacturing.
Find on Amazon ↗Tony Paquin's early work on the transformation of healthcare distribution and procurement.
Find on Amazon ↗For media inquiries, interviews, or speaking requests:
press@iremedy.comTony Paquin is available for commentary on healthcare supply chain policy, pharmaceutical manufacturing, national security, and federal procurement.
Stuart, FL - February 10, 2026 - iRemedy Healthcare Companies, Inc. ("iRemedy"), a healthcare supply chain technology company, today announced a strategic partnership with GLVUS, a Louisville, Kentucky-based advanced healthcare manufacturer focused on domestic production of premium sterile surgical gloves. The partnership will support GLVUS's entry into the U.S. market through logistics, distribution, and government contracting channels.
"As GLVUS works to onshore medical supply manufacturing and strengthen the United States' healthcare infrastructure, we are excited to partner with iRemedy," said Matthew Griffin, CEO of GLVUS. "We're confident this partnership will help GLVUS reach new markets and fuel growth while eliminating supply chain volatility to healthcare facilities across the country."
Under the partnership, iRemedy will manage logistics operations from its UPS Healthcare facility in Louisville and support distribution to federal, state, and institutional buyers through its established government sales infrastructure. GLVUS products will also be included in the iRemedy USA portfolio, providing government agencies and public-sector healthcare systems with verified access to American-made healthcare supplies.
Initial U.S. distribution will begin with UK-manufactured sterile gloves while the Louisville facility completes equipment installation and regulatory validation. Once operational, GLVUS will transition to full domestic production, including U.S.-based sterilization and warehousing.
"Strengthening American production of critical healthcare supplies is essential to ensuring resilience and quality in our national supply chain," said Tony Paquin, CEO of iRemedy. "GLVUS brings needed capability to the U.S. market, and we are pleased to support their expansion and the continued development of domestic manufacturing in Louisville."
The expansion advances both companies' shared commitment to reducing reliance on overseas medical supply production, improving quality oversight and traceability, and strengthening national preparedness for future supply chain disruptions.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — February 23, 2026 — iRemedy Healthcare Companies, Inc. ("iRemedy"), a healthcare supply chain technology company, announced today that Spectrum Medical has joined its Healthcare Supply Incubator Program.
Spectrum Medical, founded in 2006, is a global provider of advanced systems for patient monitoring, perfusion management, and clinical informatics — serving hospitals in over 60 countries. Its technologies are designed to improve outcomes in cardiovascular care by enhancing safety and workflow efficiency.
As a participant in the iRemedy Incubator, Spectrum Medical will receive full access to iRemedy's AI-driven logistics and procurement platform, streamlining its U.S. operations and expanding reach into hospital networks. The program provides tailored support across regulatory, pricing, and distribution channels to reduce barriers to entry and scale faster.
"Spectrum brings deep expertise and innovation to the cardiovascular space, and we're excited to support their next phase of growth in the U.S.," said Tony Paquin, CEO and Co-Founder of iRemedy. "Our Incubator is designed to give manufacturers like Spectrum the infrastructure and go-to-market capabilities they need to grow with confidence."
Spectrum joins a growing group of healthcare innovators in the iRemedy Incubator across device, diagnostic, and pharmaceutical sectors. The program helps emerging manufacturers navigate market complexity while accelerating access to buyers and patients.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — February 27, 2024 — iRemedy Healthcare Companies, Inc. ("iRemedy"), a pioneer in medical supply chain solutions, is pleased to announce a partnership with Welcome Baby, a charity focused on supporting low-income mothers with newborn essentials. iRemedy is committed to assemble and ship Welcome Baby's comprehensive newborn care packages, filled with critical items for the first month of a baby's life, directly to hospitals for distribution to new mothers in need.
Each care package is curated to include a variety of products such as clothes, diapers, diaper cream, wipes, bottles, a carrier, grooming kit, pacifiers, and baby wash. These items are critical in ensuring the health and comfort of newborns while providing relief to mothers during a crucial time.
"We are thrilled to join forces with Welcome Baby, an organization whose mission resonates deeply with our core values at iRemedy," said Tony Paquin, CEO of iRemedy. "By providing logistics support, we are ensuring that these much-needed supplies reach families efficiently, which is a responsibility we take to heart."
"Welcome Baby's relationship with iRemedy has been a game-changer, allowing us to reach families in need on a national level. iRemedy's smart and talented team helps us reduce our costs while still maintaining excellent quality and efficiency. We are able to reach thousands of families every year because of this partnership and we couldn't be more grateful." — Sarah Gould Steinhardt, Executive Director, Welcome Baby USA
The collaboration with Welcome Baby aligns with iRemedy's mission to alleviate supply shortages and contribute to healthier communities. It underscores the company's broader commitment to supporting underserved populations, demonstrating that the provision of medical supplies can transcend traditional healthcare settings to foster a greater social good.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — February 13, 2024 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), today announced the issuance by the United States Patent Office of a sixth key patent for its intellectual property portfolio. This brings the total number of patents protecting iRemedy's platform to six.
iRemedy is building a proprietary, highly scalable, intelligent supply chain management system for the medical supply industry. The Company began the project in 2018 as an effort to modernize and automate the inefficient and faulty medical supply distribution industry.
The United States Patent Office has granted Patent # 17/368,555 entitled Automation System and Method. The Claims covered by this patent include a system for executing a description model when utilizing a website; detecting a failure associated with the execution of the description model; re-executing the description model one or more times in an attempt to utilize the website; and if a failure is detected one or more times, reporting the failure to the user.
The Company's intellectual portfolio is comprised of two groups of patents. The first group includes four patents covering ecommerce specific AI applications. The patent announced today is the second in this group to be approved, with the other two others pending. The second group is made up of patent applications filed by an affiliate company. These patents have been assigned to iRemedy for exclusive use in healthcare and medical ecommerce industries, in perpetuity. Four of these patents are issued and seven are pending.
"Our technology has the potential to revolutionize the way medical supplies are purchased. For many years healthcare providers and their patients have suffered from product shortages and exorbitant costs," said Tony Paquin, CEO of iRemedy. "This grant by the USPO strengthens and protects our intellectual property. These technologies are key to the creation of our smart supply catalog and supply chain platform."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — November 13, 2023 — iRemedy Healthcare Companies, Inc. ("iRemedy"), a pioneer in medical supply chain solutions, has partnered with the Zoo Miami Foundation to donate a substantial inventory of medical supplies, demonstrating iRemedy's ongoing commitment to the health and well-being of all community members.
In September 2023, iRemedy provided face shields, syringes, KN95 masks, isolation gowns, and shoe covers to the Zoo Miami Foundation. The contribution directly benefits the animal patients at Zoo Miami and is a significant cost-saving for the zoo's hospital operations.
"This donation will greatly help Zoo Miami care for our patients. The 1ml and 3ml syringes are both a one-year supply of our most commonly used syringe sizes. The donation of these items will save the Zoo Miami hospital about $6,000. This will allow the team to put those funds to other needed supplies. We are incredibly grateful that iRemedy thought of us and for donating medical supplies."
Tony Paquin, CEO of iRemedy, said, "Our mission is to fill critical supply gaps, whether in human healthcare or wildlife care. This partnership with Zoo Miami Foundation is an extension of our vision to nurture healthier communities in all aspects. It's about making a positive, tangible impact where it's most needed, at any given time."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — October 2, 2023 — Demonstrating an ongoing commitment to the welfare of the community, iRemedy Healthcare Companies recently facilitated a significant donation of essential medical supplies to The Children's Museum of the Treasure Coast. This initiative is part of iRemedy's broader mission to address medical supply shortages across diverse sectors.
Among the contributions were full-length face shields, syringes, KN95 protective masks, infrared thermometers, and isolation gowns. These materials are critical in maintaining a safe and conducive learning environment, especially in settings where hands-on learning and interaction take place.
Tony Paquin, the CEO of iRemedy, remarked, "At iRemedy, we don't just cater to the needs of healthcare institutions; we see the broader picture. Addressing shortages, wherever they might be, is part of our mission. We are delighted to support The Children's Museum of the Treasure Coast and contribute to an environment where children's curiosity and learning remain unhindered."
Tammy Calabria, the Executive Director of The Children's Museum of the Treasure Coast commented, "The Children's Museum expresses profound gratitude for the invaluable contribution from iRemedy and their steadfast support as a cherished community partner. Their generous donation will persist in empowering us to craft enriching and educational experiences for the development of young minds."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — October 2, 2023 — iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), a provider of healthcare solutions, further cemented its commitment to community welfare through a donation to the Humane Society of the Treasure Coast. On September 25th, the organization received vital isolation gowns and shoe covers, reflecting iRemedy's mission to address shortages and support organizations making a difference.
The partnership with the Humane Society of the Treasure Coast, known for its dedication to nurturing the bond between people and pets, aligns seamlessly with iRemedy's ethos of community support. By ensuring that the team at the Humane Society has the necessary protective equipment, iRemedy hopes to bolster the organization's ability to care for animals in a safe and secure environment.
Tony Paquin, CEO of iRemedy, shared his thoughts, saying, "Our commitment goes beyond addressing the needs of healthcare establishments. It's about recognizing and aiding those organizations that strengthen our community's fabric. The Humane Society of the Treasure Coast does just that, and we're honored to play a role in their commendable efforts."
Sarah Fisher, Communications Manager commented, "We are so grateful to iRemedy for providing these critical supplies to our surgical unit. These supplies will allow us to continue to provide lifesaving care to the homeless animals in Martin County. We are proud to be able to partner with such generous community supporters!"
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — October 13, 2025 — Tony Paquin, Chief Executive Officer of iRemedy Healthcare Companies, testified before the U.S. Senate Special Committee on Aging on Wednesday, October 8, 2025, during a full committee hearing titled "Bad Medicine: Closing Loopholes that Kill American Patients."
Chaired by Senator Rick Scott (R-FL) and Ranking Member Senator Kirsten Gillibrand (D-NY), the hearing examined vulnerabilities in America's healthcare supply chain and explored policy solutions to close dangerous loopholes that put patient safety at risk. Paquin appeared alongside Tony Sardella, Founder & Chair of the API Innovation Center; Andrew Rechenberg, Economist with the Coalition for a Prosperous America; and Dr. Marta Wosinska, Senior Fellow at the Brookings Institution.
"This hearing marks a turning point," said Tony Paquin, CEO of iRemedy. "To protect American lives, we must bring transparency, data, and accountability into procurement — empowering manufacturers and providers to transact directly and ensuring that access to essential medicines can never again be weaponized against our nation."
In his remarks, Paquin highlighted the national security risks posed by America's heavy reliance on foreign suppliers — particularly China — for essential medical products and active pharmaceutical ingredients (APIs). He outlined how iRemedy's AI-powered procurement platform, MetaCommerceRx, enables real-time supply chain intelligence, predictive shortage detection, and direct manufacturer-to-provider transactions that enhance resilience and reduce costs.
The full hearing, "Bad Medicine: Closing Loopholes that Kill American Patients," is available on the Senate Committee on Aging's website at aging.senate.gov.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — July 22, 2025 — iRemedy, a leading medical supply chain platform and logistics partner to emerging healthcare manufacturers, today announced the launch of iRemedy USA, a national initiative designed to identify, support, and promote the growth of U.S.-based manufacturing for critical healthcare products.
This initiative addresses growing national concerns over unreliability, fragility, and national security risks associated with the globalized medical supply chain. An estimated 90% or more of all medical products consumed in the United States are manufactured abroad — predominantly in China — leaving American healthcare heavily dependent on foreign production.
"Under the leadership of President Trump, the United States is rebalancing global trade and reestablishing itself as a leading producing nation," said Tony Paquin, CEO of iRemedy. "This is especially important to the production of our essential drugs, devices, and medical supplies."
Through its iRemedy USA Portfolio Initiative, iRemedy will curate and certify a portfolio of U.S.-manufactured medical products — distinguishing them from items merely repackaged or relabeled in the U.S. — and provide seamless market access for domestic manufacturers via its patented procurement platform and UPS Healthcare-powered logistics infrastructure. The platform will enable hospitals and government buyers to identify, prioritize, and measure their purchases of domestically manufactured products.
"Today's buyers — from hospital systems to federal agencies — are actively seeking U.S.-made alternatives, but the system is opaque," Paquin said. "There's no easy way to verify if a product labeled 'Made in America' is actually manufactured here. That's a problem we're solving."
iRemedy's advocacy efforts are supported by coalition partners including Securing America's Medicines and Supply (SAMS) and the Coalition for a Prosperous America (CPA). "An alarming number of drugs are in short supply these days. Bolstering American-made pharmaceutical production will support high-paying jobs and ensure that the country isn't exposed to future supply chain breakdowns," said David Sanders, SAMS Founder and Board Member.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — July 10, 2025 — iRemedy Healthcare Companies, Inc. ("iRemedy"), a healthcare supply chain technology company, today announced that FlexGRIP, a next-generation medical device company specializing in catheter stabilization across all patient populations, has joined the iRemedy Incubator — an initiative in partnership with UPS Healthcare aimed at accelerating access to market for next-generation healthcare manufacturers.
Through the Incubator, FlexGRIP will gain access to a robust infrastructure built to support emerging companies — combining UPS Healthcare's global logistics network and cold chain capabilities with iRemedy's AI-driven procurement and distribution platform.
"Our incubator is designed to give high-potential innovators an unfair advantage," said Tony Paquin, Co-Founder and CEO of iRemedy. "FlexGRIP has developed a much needed solution that can significantly improve the delivery of care — and we're here to help them bring it to market."
Co-led by Alexander Van Damme and Steve Bierman, M.D., FlexGRIP was founded on a commitment to improving patient comfort and safety through clinically superior securement. Their flagship line of products — ranging from neonatal to adult applications — uses innovative adhesives and flexible materials that conform to the body while minimizing complications like dislodgement, skin trauma, and infection.
"We're excited to partner with iRemedy and leverage their deep understanding of healthcare logistics to get our catheter stabilization solutions into the hands of clinicians faster," said Alexander Van Damme, co-CEO and founder of FlexGRIP. "This partnership gives us the infrastructure and market access we need to focus on what we do best — improving patient outcomes."
As part of the iRemedy Incubator's latest cohort, FlexGRIP joins a growing number of startups across the device, diagnostic, pharma, and consumables sectors looking to scale faster with fewer barriers. The program provides end-to-end support — from regulatory and logistics to procurement and marketing.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — May 30, 2025 — iRemedy Healthcare Companies, Inc. ("iRemedy"), a healthcare supply chain technology company, today announced that CathCare, a medical device innovator focused on IV catheter protection solutions, has officially joined the iRemedy Incubator — a program launched in collaboration with UPS Healthcare to accelerate go-to-market strategies for emerging manufacturers.
Through this partnership, CathCare will gain full access to the Incubator's turnkey infrastructure, which includes UPS Healthcare's global capabilities, temperature-sensitive logistics, regulatory compliance support, and iRemedy's patented AI-powered technology platform.
"We built the iRemedy Incubator to remove the structural barriers that have blocked innovation from scaling in healthcare," said Tony Paquin, Co-Founder and CEO of iRemedy. "Bringing CathCare into the program allows us to support a solution that aligns with our mission — enabling efficient and transparent access to the products providers actually need."
CathCare was founded by Ellie Hunter and Kerrie Burke, who combined their diverse backgrounds to address a critical need in healthcare. "We are solving a critical issue in patient care with PortPouch," said Ellie Hunter, Founder and CEO. "This innovative product helps reduce infections and avoid dislodgement of a patient's IV Catheter, reducing pokes, readmission, and complication rates."
CathCare is one of several early-stage companies selected to join the inaugural cohort of the iRemedy Incubator, which is designed to fast-track manufacturers and reduce time to market. With dozens of companies in the pipeline, the program continues to scale its impact across diagnostics, pharmaceuticals, devices, and consumables.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — May 6, 2025 — The iRemedy Healthcare Companies, Inc. ("iRemedy"), a healthcare supply chain technology company, today announced the official start of its Incubator Solution — a first-of-its-kind program for emerging medical product companies, launched in collaboration with UPS Healthcare.
The Incubator Solution gives medical manufacturers of all sizes access to the same high-performance, healthcare-compliant infrastructure used by some of the largest players in the industry. Through this program, iRemedy enables early-stage and mid-market companies to plug into UPS Healthcare's global distribution network — complete with cold chain capabilities, regulatory compliance, warehousing, and last-mile delivery — paired with iRemedy's patented AI-powered procurement and compliance technology.
"This collaboration unlocks doors that have historically been closed to emerging manufacturers," said Tony Paquin, Co-Founder and CEO of iRemedy. "By combining UPS Healthcare's world-class logistics infrastructure with iRemedy's deep expertise in healthcare procurement, we are leveling the playing field. This is about removing friction, reducing costs, and enabling the next generation of healthcare innovation to reach providers and patients faster."
The program is currently onboarding its first cohort of participating manufacturers, with dozens more in the pipeline. "The Incubator Solution is more than a logistics offering — it's a go-to-market acceleration program," said Paquin. "We're giving small and mid-sized companies the logistics horsepower and supply chain confidence they need to grow at scale — and the market response has been phenomenal."
This milestone represents the next phase in iRemedy's broader mission to simplify and secure the healthcare supply chain while empowering innovation and improving access for healthcare providers across the country.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — January 4, 2024 — Tony Paquin is proud to announce the release of his highly anticipated new book, The End of Us: A Story of Death, Deception and China's Deadly Grip on US Healthcare. This timely and eye-opening work uncovers the hidden dangers and vulnerabilities lurking within the United States' reliance on the global medical supply chain.
In The End of Us, Tony delves deep into the complex web of dependencies that have arisen from the globalization of the medical supply chain. The book exposes how this intricate network leaves the United States vulnerable to supply disruptions, quality control issues, and competition from adversaries — serving as a stark warning of the potential consequences if these issues are not adequately addressed.
Drawing upon extensive research and firsthand accounts, Tony explores the factors contributing to the United States' growing vulnerability in the global medical supply chain. The book provides an analysis of the risks associated with foreign dependence, the erosion of domestic manufacturing capacity, and the challenges of maintaining quality control across large distances. The End of Us also highlights the potential for geopolitical tensions and trade disputes to wreak havoc on these critical supply chains, with potentially catastrophic consequences for public health and national security.
Tony Paquin is a renowned expert in the fields of medical supply chain security and technology. As CEO of iRemedy Healthcare, a leading medical supply and technology provider, Tony brings a unique and authoritative perspective informed by more than two decades of experience in healthcare supply chain operations, government contracting, and domestic manufacturing advocacy.
The End of Us is an essential read for policymakers, government agencies, healthcare professionals, and concerned citizens. The book is available now on Amazon.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — July 6, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), a leader in medical supply chain solutions, announced today that it has become a member of Securing America's Medicine and Supply (SAMS). This partnership bolsters iRemedy's commitment to enhancing transparency, efficiency, and fair pricing in the medical supplies market.
SAMS, a coalition dedicated to safeguarding America's medicines and medical supplies, is devoted to advocating for integrity, fairness, and efficiency in the medical supply industry. As a new member, iRemedy will work in tandem with other stakeholders to confront challenges, share best practices, and drive innovation in the sector.
"The issues we're facing with our medical supply chain have escalated to a level of national security concern," said Tony Paquin, CEO of iRemedy. "Our partnership with SAMS represents a proactive approach to address these dire challenges. By leveraging our technology and industry expertise, we're committed to securing America's medical supply chain, ensuring healthcare providers and patients have reliable, timely access to essential supplies."
"We are so proud to partner with iRemedy. They have long recognized the need for America to strengthen our supply chains, especially for pharmaceuticals and medical devices. They performed life-saving work through Operation Warp Speed by bringing needles and syringes from abroad for the largest pandemic in a century. We look forward to showcasing their innovative approaches to the medical marketplace," said SAMS Founder, David Sanders.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — June 15, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), a trusted and reliable partner for acquiring medical supplies, today announced the launch of their new podcast, "The Supply Side." Hosted by iRemedy CEO Tony Paquin, the podcast is an exploration of the oftentimes inefficient, problematic, and vulnerable medical supply chain and other nuances in the healthcare industry.
"The Supply Side" is now available on YouTube and accessible across all major podcast platforms. Each episode delves into an array of healthcare-related topics, with a particular focus on the complexities and challenges of the medical supply chain. The show features conversations with industry experts, healthcare professionals, policymakers, and innovators.
"Our goal with 'The Supply Side' is to expose the hidden underbelly of the medical supplies world," stated Tony Paquin, CEO of iRemedy. "It's a shocking reality that in our modern society, lives are lost due to supply shortages. This is not a case of lack of innovation, but a failure in supply chain management. Our mantra, 'Smarter Supply, Saves Lives,' emphasizes the urgency to address and rectify these challenges. We delve into the intricate processes behind sourcing and distribution, and the obstacles that hinder affordability and accessibility, because we believe these conversations are vital to save lives and improve healthcare."
The iRemedy team believes that understanding the ins and outs of the medical supply chain is a crucial part of improving healthcare outcomes. Through this podcast, the company hopes to generate awareness and stimulate dialogue that can contribute to making positive changes in the industry.
"The Supply Side" is available on YouTube and all major podcast platforms.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — September 2, 2023 — iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company") has donated over 20 million needles and close to 3 million syringes, an act set to significantly amplify healthcare initiatives across the world.
On Friday, August 18th, the alliance of World Vision, Cross Catholic Organization, and Unto Logistics Center embarked on the initial phase of this donation — collecting three truckloads, totaling 90 pallets, from iRemedy's establishment.
The prime consignment to World Vision incorporated 16,720,000 needles and 662,400 syringes. These crucial supplies will empower underserved populations across multiple regions. Additionally, iRemedy dispatched another shipment to the Unto Logistics Center and Cross Catholic Organization, contributing an additional 3,770,000 needles and 1,951,000 syringes. Further plans are being cemented for ensuing shipments, primarily concentrating on direct aid to Somalia and Mauritania via World Vision.
"By facilitating these substantial donations, we're furthering our mission of improving global healthcare access," stated Tony Paquin, CEO of iRemedy. "We're proud to collaborate with these renowned organizations, ensuring that these vital medical supplies reach the communities that need them most."
Jennifer Hawley, Sr. Director, Corporate Engagement, remarked, "The donation of syringes and needles from iRemedy could not have come at a better time! In Mauritania, the donation will be used in expanded vaccination programs across the country. In Somalia, World Vision is working with the government to launch a tuberculosis vaccination program which will be resourced by the iRemedy donation. World Vision is grateful to the iRemedy leadership for their generosity and for the dedication of their staff which has made this possible."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — September 25, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), today announced the issuance by the United States Patent Office of a fifth key patent for its intellectual property portfolio.
iRemedy is building a proprietary, highly scalable, intelligent supply chain management system for the medical supply industry. The Company began the project in 2018 as an effort to modernize and automate the inefficient and faulty medical supply distribution industry.
The United States Patent Office has granted Patent # 17/368,546 entitled Automation System and Method. The Claims covered by this patent include a system for tracking how data on the target site is changing and how to intelligently manage the monitoring and extraction of any changing data. This gives iRemedy additional protection, exclusive to them, on how to manage and extract data from computers worldwide.
The Company's intellectual portfolio is comprised of two groups of patents. The first group includes four patents covering e-commerce-specific AI applications. The patent announced today is the first in this group approved, with the other three pending. The second group is made up of patent applications filed by affiliate Grokit Data, Inc. These patents have been assigned to iRemedy for exclusive use in healthcare and medical ecommerce industries, in perpetuity. Four of these patents are issued and seven are pending.
"Our technology has the potential to revolutionize the way medical supplies are purchased. For many years healthcare providers and their patients have suffered from product shortages and exorbitant costs," said Tony Paquin, CEO of iRemedy. "This grant by the USPO strengthens and protects our intellectual property. These technologies are key to the creation of our smart supply catalog and supply chain platform."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — June 26, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), an artificial intelligence-powered medical supply chain solution, today announced the issuance by the United States Patent Office of a key patent for its intellectual property portfolio.
iRemedy is building a proprietary, highly scalable, intelligent supply chain management system for the medical supply industry. The Company began the project in 2018 as an effort to modernize and automate the inefficient and faulty medical supply distribution industry.
The United States Patent Office has granted Patent # 11416575 which protects a means of automated navigation for crawling the World Wide Web using the ParaLogue and ParaFlow languages. ParaFlow and ParaLogue are proprietary languages designed for modeling web pages and processing workflows and are protected for iRemedy's use by additional patent applications.
The Patent application was filed by Grokit Data, Inc. and has been licensed to iRemedy for exclusive use in the medical ecommerce and supply chain market. Grokit Data was founded by iRemedy's CEO Tony Paquin, and CTO Jim Harding as a research entity working on AI technologies.
"Our technology has the potential to truly revolutionize the way medical supplies are acquired in this country. For many years healthcare providers and their patients have suffered from product shortages and exorbitant costs," said Tony Paquin, CEO of iRemedy. "This grant by the USPO strengthens and protects our intellectual property. These technologies are essential to the automated sourcing and offering of medical products through our platform."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — June 27, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), a pioneer in the medical supply ecommerce industry, and Verséa Health, a leading provider of diagnostics and medical supplies for urgent care centers, are pleased to announce a strategic joint venture aimed at providing an integrated ecosystem of services designed uniquely to serve and enable the continued growth of urgent care facilities nationwide.
The venture aims to address inefficiencies in the procurement process, bringing a much-needed solution to urgent care providers. The collaboration will leverage iRemedy's industry-leading procurement technology and Verséa's deep understanding of the urgent care sector to deliver a specialized platform that simplifies, streamlines, and enhances the supply purchasing process.
Tony Paquin, CEO of iRemedy, commented, "This partnership with Verséa is a significant step forward in our commitment to revolutionize the healthcare supply chain. By combining our respective strengths, we're confident that our new platform will significantly improve the procurement process, allowing urgent care providers to focus more on their primary mission — patient care."
Sean Fetcho, CEO of Verséa Health, added, "Verséa Health was born from a desire to transform healthcare to improve quality and access to care, and we believe urgent care centers are on the frontlines of much of that change. Partnering with iRemedy and utilizing their robust ecommerce infrastructure allows us to deliver a seamless, efficient, and effective solution."
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
Stuart, FL — June 6, 2023 — The iRemedy Healthcare Companies, Inc. ("iRemedy" or "the Company"), an artificial intelligence powered medical supply chain solution, today announced the launch of their capital raise program on the Republic crowdfunding platform.
This strategic decision underscores iRemedy's commitment to growth and inclusivity, offering both accredited and non-accredited investors the opportunity to invest in the Company. The Company has been experiencing high growth in the medical supply market because of its patent protected supply chain solution.
"Our technology has the potential to truly revolutionize the way medical supplies are acquired in this country. For many years healthcare providers and their patients have suffered from product shortages and exorbitant costs. We are excited to partner with Republic for our capital raise program," said Tony Paquin, CEO of iRemedy. "This Regulation A offering will not only fuel our growth plans but also aligns with our philosophy of democratizing access — be it for medical supplies or investment opportunities."
Republic's crowdfunding platform is a renowned space that offers a seamless and secure investment process. It enables startups and established companies to raise capital by offering securities to retail investors, widening the pool of potential investors, and bringing in a diverse group of stakeholders.
With this partnership, iRemedy continues to move forward with its vision of making medical supply procurement more affordable, reliable, and efficient. For more information on iRemedy's Regulation A offering, please visit the Republic.com/iremedy platform.
iRemedy Healthcare Companies, Inc. is a technology-enabled healthcare distributor providing direct pharmaceutical and medical product distribution, AI-powered procurement intelligence, and supply chain transparency services. Founded in 2013, iRemedy is licensed in all 50 states, NABP accredited, and DSCSA compliant. iRemedy's logistics infrastructure is powered by UPS Healthcare. Learn more at iremedy.com.
